share_log

Autolus Therapeutics Receives PRIME Designation From EMA For AUTO1 For The treatment Of Adult ALL

Autolus Therapeutics Receives PRIME Designation From EMA For AUTO1 For The treatment Of Adult ALL

Autolus Treateutics获得EMA颁发的治疗成人ALL的AUTO1最佳称号
Benzinga Real-time News ·  2021/04/01 20:48

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).

开发下一代程序化T细胞疗法的临床阶段生物制药公司Autolus Treeutics plc(纳斯达克市场代码:AUTL)今天宣布,它已获得欧洲药品管理局(EMA)指定的治疗AUTO1的优先药物(PRIME),该公司的CAR T细胞疗法正在进行的Felix 1b/2期复发/难治性成人B急性淋巴细胞白血病(ALL)研究中接受调查。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发